Overall and progression-free survival of patients with metastatic colorectal cancer: A real‑world prospective, longitudinal cohort study on the continuum of care (PROMETCO)

Data presented at the ESMO Congress 2023

M Koopman,1 R Garcia-Carbonero,2 C Pinto,3 A Mitroshkin,4 G Bodoky,5 L Mineur,6 V Bourgeois,7 M Mare,8 A Ruiz-Casado,9 A Fernandez Montes,10 JM O’Connor,11 A Sullivan,12 E Choucair,13 M Sicaire,13 F Marti Marti,14 JB Bachet15

1. Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University Heidelberglaan 100 3584 CX Utrecht, the Netherlands; 2. Hospital Universitario Doce de Octubre Imas12, UCM, Avenida De Córdoba s/n, 28041 Madrid, Spain; 3. Medical Oncology, Clinical Cancer Centre Azienda USL – IRCCS di Reggio Emilia – Viale Risorgimento, 80 42123 Reggio Emilia, Italy; 4. Klinikum Freudenstadt, Akademisches Lehrkrankenhaus der Universität Tübingen, Karl-von-Hahn Strasse, 120, 72250 Freudenstadt, Germany; 5. Dél-Pesti Centrumkórház Szent László Telephely Albert Flórián út 5–7 1097 Budapest, Hungary; 6. GI and Liver Oncology Unit, Institut of Cancer Sainte Catherine Avignon Provence, France; 7. Boulogne-sur-Mer Hospital Center, Rue Jacques Monod, 62200 Boulogne-sur-Mer, France; 8. Medical Oncology Unit, Mediterranean Institute of Oncology, Viagrande, I-95029 Catania, Italy; 9. Department of Medical Oncology, Hospital Universitario Puerta de Hierro, E-28220 Madrid, Spain; 10. Complexo Hospitalario Universitario de Ourense, Calle Ramon Puga Noguerol, 54, 32005, Orense, Spain; 11. Instituto Alexander Fleming, Buenos Aires, Argentina; 12. Servier Pharmaceuticals, 200 Pier 4 Blvd, Boston, MA 02210, USA; 13. Servier, 35 rue Verdun, 92284 Suresnes, France; 14. The Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester M20 4BX, UK; 15. Sorbonne Université, Service d’hépato-Gastro-Entérologie, Groupe Hospitalier Pitié Salpêtrière, APHP, Paris, France

back to top

PROMETCO: Introduction and aim

  • The primary treatment goal for patients with unresectable mCRC is tumor shrinkage and disease control with preservation or improvement of quality of life1

  • Clinical emphasis lies in avoidance of rapid disease evolution, and prolonging survival1

  • Advances in mCRC treatment have now improved median OS to 30 months in clinical trials1

  • PROMETCO (NCT03935763) is the first international, prospective real-world study to investigate the continuum of care in the mCRC patient population, collecting data on all patients with two disease progressions, regardless of treatment or age


  • To present preliminary real-world clinical characteristics and treatment patterns of 738 patients with mCRC that has progressed twice on previous treatment

  • To show OS and PFS of the 655/738 patients with mCRC who have completed the study

  • Inclusion criteria: Adult patients with two disease progressions since the first diagnosis of metastatic disease, suitable to receive subsequent treatment, were included

  • Exclusion criteria: Patients enrolled in other clinical trials, receiving treatment for other cancers, or those with reduced mental capacity were excluded

mCRC, metastatic colorectal cancer.
1. Van Cutsem E, et al. Ann Oncol. 2016;27:1386–422.

Patient characteristics in PROMETCO

back to top

Biomolecular status

Age and sex


Disease characteristics


Efficacy data on 89% of the population

back to top


OS from mCRC diagnosis

OS from inclusion in PROMETCO

OS from third treatment line

Take-home messages

back to top